Haloperidol Esteve (Haloperidol)

Haloperidol Esteve is indicated for several psychiatric disorders where dopamine blockade can reduce symptoms.

• Schizophrenia, including maintenance therapy for chronic illness.
• Acute psychotic episodes, such as those associated with bipolar disorder or substance‑induced psychosis.
• Manic episodes in bipolar I disorder when rapid control of agitation is required.
• Severe agitation or aggression that poses a risk to the patient or others.
• Tourette syndrome, particularly for patients with disabling motor or vocal tics.
• Adjunctive treatment of certain refractory cases of obsessive‑compulsive disorder (off‑label).

The safety profile of Haloperidol Esteve reflects its pharmacologic activity on multiple neurotransmitter receptors.

Common

• Drowsiness or sedation
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia
• Dry mouth and constipation
• Blurred vision
• Weight gain or increased appetite

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction
• Tardive dyskinesia, characterized by involuntary movements
• Severe hypotension or orthostatic dizziness
• Cardiac arrhythmias, including QT prolongation
• Agranulocytosis or severe leukopenia

Before prescribing Haloperidol Esteve, clinicians should evaluate patient history and monitor for potential risks associated with its antipsychotic activity.

• Assess for cardiovascular disease, as haloperidol may cause QT prolongation.
• Use caution in patients with a history of seizures or epilepsy.
• Evaluate liver and renal function; dose adjustments may be needed in impairment.
• Monitor for signs of extrapyramidal side effects, especially in the elderly.
• Avoid use during pregnancy unless benefits outweigh risks, due to limited safety data.
• Screen for diabetes or metabolic syndrome, as weight changes can occur.
• Consider baseline and periodic blood counts to detect rare hematologic effects.

Haloperidol Esteve can interact with other medications that influence its metabolism or amplify its pharmacodynamic effects.

Avoid

• Other dopamine antagonists or antipsychotics, which may increase extrapyramidal risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.
• Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution

• CNS depressants including benzodiazepines or opioids, which can enhance sedation.
• Antihypertensive agents, because additive hypotensive effects may occur.
• Drugs that affect electrolyte balance (e.g., diuretics) increasing risk of cardiac arrhythmias.